ClinicalTrials.gg
Sign In
DrugRead study by study

Durvalumab clinical trials

Also written MEDI4736 and Imfinzi.

studies test it
481
open now
115
in phase 3
62
first study started
2010
ClinicalTrials.gov finds 922 studies for durvalumab. How that becomes 481 here

Every study that search finds has been read, apart from the 4 newest, to see whether and how it gives durvalumab. ClinicalTrials.gov counts as of Nov 13, 2026. How drug pages count

  1. 922Found by its intervention search · See all 922 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 822 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −1
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. −1New since the last reading, not read yet
  4. 920Give durvalumab to participants
  5. −79Observe patients on it, or give it outside a trial
  6. −1Use it as a tool: an imaging tracer or a test of drug response
  7. −21Compare another treatment with it
  8. −338Give it beside what is tested
  9. 481Test it: the count on this site

Get an email when these change. Save the durvalumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 May 2017 · IMFINZI · BLA 761069 (FDA, Drugs@FDA)
European Union
21 Sept 2018 · Imfinzi · EMEA/H/C/004771 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Durvalumab
345
Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer
43
Durvalumab (MEDI4736)
5
MEDI4736 (Durvalumab)
5
Durvalumab Injection
4

Brand

Imfinzi
104

Development codes

MEDI4736
184

In one entry with another drug

Given together, or one or the other

Durvalumab + Tremelimumab
3
MEDI4736 + Tremelimumab
3
MEDI4736+Tremelimumab
2
ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
2
Other ICIs
2

Studies by the year they started

480 studies that test it; most in 2018 (51); 1 more planned to start later

Studies that test durvalumab, by start year
YearStudies
20101
20121
20134
201416
201527
201650
201745
201851
201946
202047
202148
202226
202340
202438
202517
202623

By phase

A phase 1/2 study counts in both.

Early Phase 1
7
Phase 1
112
Phase 2
342
Phase 3
62
Phase 4
5
No phase
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
76
Carcinoma, Hepatocellular
36
Small Cell Lung Carcinoma
26
Breast Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
15
Cholangiocarcinoma
14
Urinary Bladder Neoplasms
13
Colorectal Neoplasms
10
Pancreatic Neoplasms
10
Biliary Tract Neoplasms
10
Triple Negative Breast Neoplasms
10
Lung Neoplasms
9

Who runs them

Industry 106 · Other 375

AstraZeneca (75) · National Cancer Institute (NCI) (15) · MedImmune LLC (13) · Memorial Sloan Kettering Cancer Center (11) · M.D. Anderson Cancer Center (11) · Canadian Cancer Trials Group (10) · Celgene (8) · UNICANCER (6)

Often tested with

Tested in the same studies.

Tremelimumab (121) · Olaparib (37) · Cisplatin (19) · Carboplatin (16) · Lenvatinib (13) · Etoposide (12) · Paclitaxel (12) · Gemcitabine (12)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 13 phase 3 studies under way

Durvalumab is the comparator. A study of two new drugs counts under both.

  • 3Rilvegostomig · AstraZeneca · next primary completion Jun 2028
  • 2Ivonescimab · Akeso, ECOG-ACRIN Cancer Research Group · next primary completion Dec 2028
  • 1Alectinib · Hoffmann-La Roche · next primary completion Jan 2027
  • 1Entrectinib · Hoffmann-La Roche · next primary completion Jan 2027
  • 1Livmoniplimab · AbbVie · next primary completion Jan 2027
  • 1Budigalimab · AbbVie · next primary completion Jan 2027
  • 1Pembrolizumab · Merck Sharp & Dohme LLC · next primary completion May 2027
  • 1Olaparib · Merck Sharp & Dohme LLC · next primary completion May 2027
New treatments tested with it · 8 most studied

New when their studies opened, with durvalumab beside them; studies of each.

Reaching primary completion within a year · 56, 7 in phase 3

Studies that test durvalumab, phase 3 first.

Studies

Open first, then newest update. How each study uses durvalumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 481

See all 481 studies that test durvalumab →

Behind its US label · 11 — the studies the FDA label of IMFINZI describes

From the Clinical Studies section of IMFINZI (2026-08), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 110 — no other medicine in its arm

Showing 20 of 110. See all 110 →

Tested with established drugs · 76 — they are given beside it

Showing 20 of 76. See all 76 →

Tested in a combination · 295 — another drug in the study is under test too

Showing 20 of 295. See all 295 →

Beside an established treatment under test · 78 — an approved drug, surgery or radiation is what the study tests

Tested with durvalumab: Radiation 33 · Surgery or a procedure 10 · A device 7 · Cisplatin 5 · trastuzumab deruxtecan 4 · AMG 757 3 · olaparib 3 · Gemcitabine 3

Showing 20 of 78. See all 78 →

Beside a new treatment under test · 248 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with durvalumab: tremelimumab 66 · ceralasertib 17 · oleclumab 14 · monalizumab 8 · datopotamab deruxtecan 5 · danvatirsen 5 · savolitinib 4 · Durvalumab/Tremelimumab Regimen 4

Showing 20 of 248. See all 248 →

Beside supportive care · 4 — a supportive treatment or test is studied
One option of several · 6 — a test or a strategy chooses among drugs
Given beside what is tested · 2 — usual care or a partner of the new treatment
As the comparator · 21 — what is tested is compared with durvalumab

Showing 20 of 21. See all 21 →

Observed · 79 — patients on it are followed, or it is given outside a trial

Showing 20 of 79. See all 79 →

As a tool · 1 — an imaging tracer or a test of drug response

Codes

What other systems call durvalumab · ClinicalTrials.gg INT000587

  • MeSH (NLM) C000613593durvalumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 28X28X9OKVDURVALUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1919503Confirmed FDA, Wikidata
  • Wikidata Q19904005durvalumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C103194DurvalumabOne source FDA
  • DrugBank DB11714One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion